Journal: Frontiers in Immunology

Article Title: R3HDM4 influences kidney renal clear cell carcinoma progression, immune modulation, and potential links to the IGSF8 immune checkpoint

doi: 10.3389/fimmu.2025.1722358

Figure Lengend Snippet: R3HDM4 silencing modulates expression of EMT, invasion, and immune-related markers in 786-O cells. (A) Representative Western blot of E-cadherin, MMP-2, MMP-9, Vimentin, IGSF8 and GAPDH in 786-O (control), 786-O+si-NC (negative control siRNA), and 786-O+si-R3HDM4-4 (R3HDM4-targeting siRNA) groups. (B) Quantification of relative E-cadherin expression across 786-O, si-NC, and si-R3HDM4–4 groups. (C) Quantification of relative MMP-2 expression across 786-O, si-NC, and si-R3HDM4–4 groups. (D) Quantification of relative MMP-9 expression across 786-O, si-NC, and si-R3HDM4–4 groups. (E) Quantification of relative Vimentin expression across 786-O, si-NC, and si-R3HDM4–4 groups. (F) Quantification of relative IGSF8 expression across 786-O, si-NC, and si-R3HDM4–4 groups. P - values were determined by one-way ANOVA; ** P < 0.001 indicates statistical significance.* P < 0.05, ** P < 0.01, *** P < 0.001. CTRL, control untreated; si-NC, negative control siRNA; si-R3HDM4, R3HDM4-targeting siRNA; E-cadherin, epithelial cadherin; MMP-2/9, matrix metalloproteinase-2/9; IGSF8, Immunoglobulin Superfamily Member 8 expression.

Article Snippet: The primary antibodies used were: R3HDM4 (29 kDa, 1:1000, Invitrogen, USA), GAPDH (36 kDa, 1:10,000, Proteintech, China), E-cadherin (125 kDa, 1:40,000, Proteintech, China), Vimentin (55 kDa, 1:40,000, Proteintech, China), MMP2 (63 kDa, 1:1000, BIOSS, China), MMP9 (78 kDa, 1:1000, Affinity, USA), and IGSF8 (70 kDa, 1:2000, Proteintech, China).

Techniques: Expressing, Western Blot, Control, Negative Control

Journal: Journal of nanobiotechnology

Article Title: Radiotherapy-derived engineered stem cell exosomes improve anti-glioma immunotherapy by promoting the formation of tertiary lymphoid structure and improve the release of type I interferon.

doi: 10.1186/s12951-025-03301-5

Figure Lengend Snippet: Fig. 2 Preparation and characterization of BafA1@Rexo-SC. A Schematic of BafA1@Rexo-SC preparation. B Schematic diagram of a plasmid constructed to express both membrane-anchored anti-CD47 nanobodies and STING proteins, and the representative images for the location of anti-CD47 nanobodies and STING proteins in mouse bone marrow-derived stem cells (MSCss) by confocal imaging, scale bar: 10 μm. C Size distribution of different engineered exosomes measured by dynamic light scattering. D Zeta potential of different engineered exosomes measured by Malvern laser particle size analyzer. E Size distribution of different engineered exosomes measured by transmission electron microscopy, scale bar: 50 nm. F Analysis of the expression of Alix, CD81, CD63, STING, Phosphorylating STING (pSTING) and EGFP in different engineered exosomes by using western blotting experiment. G HPLC to be used to identify the drug release characteristics of BafA1@Rexo-SC. Data are presented as the mean ± SD. *P < 0.05,**P < 0.01, ***P < 0.001, and NS: not significant

Article Snippet: For western blot, primary antibodies STING, p-STING, NFκB and p-NFκB were purchased from ABclonal (Boston, MA, USA) and GAPDH, CD63, CD81 and Alix were obtained from Proteintech Group, Inc. (Chicago, IL, USA).

Techniques: Plasmid Preparation, Construct, Membrane, Derivative Assay, Imaging, Zeta Potential Analyzer, Transmission Assay, Electron Microscopy, Expressing, Western Blot